Yu Wang

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 10

Top Topics

Atopic Dermatitis

Drug Administration

Top Venues

Dermatologic therapy

International journal of dermatology

Journal of cutaneous medicine and surgery

This page only lists publications with an associated author ORCID identifier.

Publications

April Lee, Yu Wang, Cajeton Nadarajah, Shari R Lipner
Scalp and hair burns have high admission rates and disproportionally affect females and children in a cross-sectional analysis of NEISS 2000-2018. International journal of dermatology (2022)
Yu Wang, Joseph L Jorizzo
Retrospective analysis of ocular adverse events with Clobetasol. Dermatologic therapy 35 (7) (2022)
Yu Wang, Shari R Lipner
Retrospective analysis of nail biopsies performed using the Medicare Provider Utilization and Payment Database 2012 to 2017. Dermatologic therapy 34 (3) (2021)
Yu Wang, Joseph Jorizzo
Retrospective analysis of ocular adverse events with topical hydrocortisone when used for dermatologic indications. Dermatologic therapy (2021)
Yu Wang, Joseph Jorizzo
Retrospective analysis of adverse events with mycophenolate mofetil and methotrexate when used for dermatologic indications. International journal of dermatology (2021)
Yu Wang, Joseph Jorizzo
Difference in the rate of ocular adverse events with dupilumab between asthma and atopic dermatitis patients. International journal of dermatology 60 (9) (2021)
Yu Wang, Shari R Lipner
Retrospective study of ultraviolet indices and incidence of melanoma in the United States. International journal of dermatology (2021)
Yu Wang, Shari R Lipner
Retrospective analysis of squamous cell carcinoma associated with ingenol mebutate reported to the US Food and Drug Administration. Dermatologic therapy 33 (6) (2020)
Yu Wang, Shari R Lipner
Visual Dermatology: A Case of Bilateral Onychogryphosis With Characteristic Dermoscopic Findings. Journal of cutaneous medicine and surgery 25 (2) (2020)
Yu Wang, Shari R Lipner
Google trends analysis of public interest in biotin for dermatological conditions following the FDA warning. Dermatologic therapy 33 (6) (2020)